Core Laboratories Inc. CLB is set to release second-quarter earnings on Jul 24, after the closing bell. The Zacks Consensus Estimate for the to-be-reported quarter is a profit of 22 cents per share on revenues of $133.34 million. Let’s delve into the factors that might have influenced CLB’s performance in the to-be-reported quarter. Before that, it’s worth taking a look at the company’s performance in the last reported quarter. Highlights of Q1 Earnings In the last reported quarter, the Houston, TX-based oil and gas equipment and services company’s earnings beat the consensus mark. CLB reported adjusted earnings of 19 cents per share, which was 3 cents higher than the Zacks Consensus Estimate. This can be attributed to robust performance from the Reservoir Description segment. Revenues of $129.6 million also beat the Zacks Consensus Estimate by 4.5%. CLB’s earnings beat the Zacks Consensus Estimate in two of the trailing four quarters and missed the mark in two, delivering an average earnings surprise of 3.6%. Core Laboratories Inc. Price and EPS Surprise Core Laboratories Inc. Price and EPS Surprise Core Laboratories Inc. price-eps-surprise | Core Laboratories Inc. Quote Trend in Estimate Revision The Zacks Consensus Estimate for second-quarter 2024 earnings has witnessed an upward and a downward movement in the past 30 days. The estimated figure indicates a 4.76% year-over-year increase. The Zacks Consensus Estimate for revenues indicates an increase of 3.49% from the prior-year reported figure. Factors to Consider CLB’s revenues are likely to have improved in the quarter to be reported. Our model predicts revenues to increase to $133 million from the prior-year recorded level of $129.6 million. This can be attributed to the strong performance of the Reservoir Description segment. On the other hand, the company’s operating expenses are projected to have reached $118.4 million, up 8.7% from the year-ago period’s level. Its direct operating costs (which include labor, materials or supplies) are expected to have increased from $100.3 million to $104.6 million in the same time frame. This rise in expenses across the economy might have affected the company's overall profitability despite the revenue growth. What Does Our Model Predict? The proven Zacks model does not conclusively predict an earnings beat for Core Laboratories this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. However, that’s not the case here. Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate, for this company is -2.33%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: CLB currently carries a Zacks Rank #3. Stocks to Consider Here are some firms that you may want to consider, as these have the right combination of elements to post an earnings beat this reporting cycle. Coterra Energy CTRA has an Earnings ESP of +3.57% and a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank stocks here. CTRA is scheduled to release earnings on Aug 1. It has a trailing four-quarter average earnings surprise of 9.81%. Valued at around $20.37 billion, CTRA’s shares have risen 2.1% in a year. Expro Group Holdings XPRO currently has an Earnings ESP of +2.04% and a Zacks Rank #2. The firm is scheduled to release earnings on Jul 25. XPRO has a trailing four-quarter average earnings surprise of 78.41%. Valued at around $2.68 billion, XPRO’s shares have risen 10.9% in a year. Pembina Pipeline PBA has an Earnings ESP of +9.09% and a Zacks Rank #2 at present. The firm is scheduled to release earnings on Aug 8. PBA has a trailing four-quarter average earnings surprise of 10.91%. Valued at around $21.79 billion, PBA’s shares have risen 21.8% in a year. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Core Laboratories Inc. (CLB):Free Stock Analysis Report Pembina Pipeline Corp. (PBA):Free Stock Analysis Report Coterra Energy Inc. (CTRA):Free Stock Analysis Report Expro Group Holdings N.V. (XPRO):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
What's in Store for Core Laboratories (CLB) in Q2 Earnings?
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...